Variable | 30-day outcome | P-value | |
---|---|---|---|
Survived (n = 213) | Died (n = 30) | ||
Age,years (range) | 57.8(17–91) | 62.7(29–81) | 0.127 |
Gender (male:female) | 124:89 | 15:15 | 0.394 |
Underlying comorbidities (n, %) | |||
 Gastrointestinal perforation | 39 (18.3) | 9 (30.0) | 0.132 |
 Respiratory dysfunction | 31 (14.6) | 20 (66.7) | < 0.001 |
 Pulmonary infection | 63 (29.6) | 18 (60.0) | 0.001 |
 Cardiovascular disease | 58 (27.2) | 20 (66.7) | < 0.001 |
 Neurological diseases | 47 (22.1) | 11 (36.7) | 0.079 |
 Gastrointestinal pathology | 56 (26.3) | 7 (23.3) | 0.729 |
 Chronic/acute liver disease | 36 (16.9) | 9 (30.0) | 0.084 |
 Chronic/acute renal failure | 74 (34.7) | 16 (53.3) | 0.048 |
 Solid tumour | 19 (8.9) | 3 (10.0) | 0.847 |
 Haematological malignancy | 5 (2.3) | 1 (3.3) | 0.991 |
 Severe autoimmune diseases | 8 (3.8) | 3 (10.0) | 0.124 |
 Diabetes mellitus | 79 (37.1) | 14 (46.7) | 0.312 |
 Burns | 5 (2.3) | 1 (3.3) | 0.745 |
 HIV/AIDS | 11 (5.2) | 2 (6.7) | 0.732 |
 Severe trauma | 13 (6.1) | 2 (6.7) | 0.904 |
Risk factors (n,%) | |||
 Presence of CVC | 104 (48.8) | 14 (46.7) | 0.825 |
 Mechanical ventilation | 67 (31.5) | 15 (50.0) | 0.044 |
 Receipt of corticosteroids | 58 (27.2) | 12 (40.0) | 0.148 |
 Total parenteral nutrition | 100 (46.9) | 19 (63.3) | 0.093 |
 Chemotherapy | 10 (4.7) | 1 (3.3) | 0.737 |
 Abdominal surgery | 67 (31.5) | 2 (6.7) | 0.005 |
 In the ICU at diagnosis | 30 (14.1) | 12 (40.0) | < 0.001 |
 Neutropenia | 5 (2.3) | 2 (6.7) | 0.185 |
 Concomitant bacterial infections | 67 (31.5) | 14 (46.7) | 0.098 |
 Septic shock | 35 (16.4) | 11 (36.7) | 0.008 |
 Dialysis | 21 (9.9) | 4 (13.3) | 0.558 |
 Prior exposure to broad-spectrum antibiotics | 188 (88.3) | 27 (90.0) | 0.780 |
 Treatment with antifungal agents | 71 (33.3) | 12 (40.0) | 0.471 |
Species, n (%) | |||
  C. albicans | 90 (42.3) | 20 (66.7) | 0.012 |
  C. glabrata | 67 (31.5) | 6 (20.0) | 0.200 |
  C. tropicalis | 34 (16.0) | 3 (10.0) | 0.395 |